Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide ...

MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

It won't come as a surprise to anyone to hear that quite a few quality stocks have performed terribly this year. Some have ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

In the wake of early evidence supporting the long-term health benefits of GLP-1 based medications to potentially reduce the ...

Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken any time of the day without ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...